310 results on '"Sorce, Gabriele"'
Search Results
52. PD10-09 A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION
53. MP40-14 ARE EAU RISK GROUPS RELIABLE IN THE STRATIFICATION OF MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND RESTAGED WITH PSMA-PET?
54. MP40-07 HAS THE INTRODUCTION OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE AND TARGETED BIOPSIES LED TO A RISK OF OVERGRADING OF HIGH RISK PROSTATE CANCER? RESULTS FROM A CONTEMPORARY LARGE MULTI-INSTITUTIONAL SERIES.
55. MP11-11 TAILORING THE OPTIMAL USE OF ANDROGEN-DEPRIVATION THERAPY CONCOMITANT TO POST-OPERATIVE RADIOTHERAPY AMONG MEN WITH PN1 PROSTATE CANCER. LONG-TERM RESULTS OF A LARGE, SINGLE INSTITUTION SERIES
56. PD39-10 THE ASSOCIATION BETWEEN PSA DENSITY AND THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER ACROSS ALL PIRADS SCORES IN MEN WITH POSITIVE MPMRI. WHEN PSA DENSITY CAN HELP AVOIDING PROSTATE BIOPSY?
57. MP38-11 IS THERE AN IMPACT OF THE CENTER PERFORMING BASELINE MULTIPARAMETRIC MRI ON ACTIVE SURVEILLANCE OUTCOMES IN PROSTATE CANCER PATIENTS?
58. MP67-04 VALIDATION OF NOVEL PREOPERATIVE RISK CATEGORIES ON THE PREDICTION OF CLINICAL RECURRENCE IN PATIENTS CANDIDATE FOR RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES
59. MP11-08 EXPLORING THE EFFECT OF METASTASIS DIRECTED THERAPY ON PROGRESSION PATTERNS OF PATIENTS WITH POSITIVE 68Ga-PSMA PET/CT AND BIOCHEMICAL RECURRENCE FROM PROSTATE CANCER
60. MP67-07 CAN WE PREDICT THE SITE OF POSITIVE SURGICAL MARGINS (PSM) BASED ON THE SITE OF THE INDEX LESION AT MULTIPARAMETRIC MRI? A TOPOGRAPHIC SINGLE CENTER STUDY
61. PD39-09 IMPACT OF PROSTATE IMAGING QUALITY (PI-QUAL) SCORE ON THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN UNDERGOING MRI-TARGETED BIOPSY
62. The association of type and number of high‐risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy
63. The Effect of Sex on Disease Stage and Survival after Radical Cystectomy in Non-Urothelial Variant-Histology Bladder Cancer
64. Cancer-specific Mortality After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma
65. Robotic-assisted uretero-ileal reimplantation for benign ureteral strictures in patients with prior minimally-invasive radical cystectomy and intracorporeal urinary diversion
66. Racial/ethnic disparities in the distribution and effect of type and number of high-risk criteria on mortality in prostate cancer patients treated with radiotherapy.
67. The effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy
68. Racial/ethnic disparities in the distribution and effect of type and number of high-risk criteria on mortality in prostate cancer patients treated with radiotherapy
69. Effect of positive surgical margins at radical prostatectomy on cancer‐specific mortality in high/very high‐risk prostate cancer patients with Gleason Grade Group 4–5
70. Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registries
71. The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy
72. Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma
73. Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial Nephrectomy
74. Outcomes of robotic‐assisted versus open radical cystectomy in a large‐scale, contemporary cohort of bladder cancer patients
75. Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level
76. MP53-04 RATES OF UPGRADING AND UPSTAGING IN PROSTATE CANCER PATIENTS WITH SINGLE GGG1 POSITIVE BIOPSY CORE
77. Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients
78. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients
79. Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups
80. Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients
81. Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups
82. Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates
83. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients
84. Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer
85. Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series
86. MP51-08 DOES A POSITIVE MULTI-PARAMETRIC MRI ALWAYS WARRANT PROSTATE BIOPSY? THE IMPORTANCE OF INTEGRATING CLINICAL AND IMAGING DATA BASED ON A LARGE, MULTI-INSTITUTIONAL SERIES
87. MP43-19 DROP-OUT RATES FROM ACTIVE SURVEILLANCE FOR DISEASE PROGRESSION REMAIN CONSISTENT AND NOT NEGLIGIBLE OVER TIME. A PLEA FOR LONG-TERM ASSESSMENT BASED ON A LARGE, PROSPECTIVELY COLLECTED ACTIVE SURVEILLANCE COHORT
88. PD60-11 IMPACT OF THE TIME ELAPSED BETWEEN PROSTATE BIOPSY AND SURGERY ON THE ACCURACY OF THE BRIGANTI NOMOGRAM PREDICTING LYMPH NODE INVASION IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER
89. MP53-01 DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN MPMRI VISIBLE LESIONS: SIZE MATTERS. RESULTS FROM A LARGE, TWO-INSTITUTIONAL SERIES
90. PD60-04 SURVIVAL AFTER RADICAL PROSTATECTOMY VS. RADIATION THERAPY IN CLINICAL NODE-POSITIVE PROSTATE CANCER
91. PD60-10 A MORE EXTENDED PELVIC LYMPH NODE DISSECTION DECREASES RECURRENCE RATES IN SELECTED PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY
92. MP51-11 HAS THE INTRODUCTION OF MPMRI IN THE DIAGNOSTIC PATHWAY OF PROSTATE CANCER LED TO IMPROVED ONCOLOGICAL OUTCOMES AFTER RADICAL PROSTATECTOMY? RESULT FROM A LARGE SINGLE-INSTITUTIONAL SERIES
93. MP27-02 NOT ALL ADVERSE PATHOLOGY FEATURES ARE EQUAL: IDENTIFYING OPTIMAL CANDIDATES FOR ADJUVANT RADIOTHERAPY AMONG PATIENTS WITH ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY
94. PD60-03 THE IMPACT OF HISTOLOGICAL VARIANTS ON THE PERFORMANCE CHARACTERISTICS OF 68GA-PSMA PET/CT IN THE PRIMARY AND RECURRENT SETTING
95. MP51-14 IMPACT OF 68GA-PSMA PET/CT AND METASTASIS-DIRECTED THERAPY ON CLINICAL RECURRENCE IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. RESULTS FROM A SINGLE CENTER SERIES
96. MP03-10 LIFE EXPECTANCY IN METASTATIC UROTHELIAL BLADDER CANCER PATIENTS ACCORDING TO RACE/ETHNICITY
97. MP51-20 THE ASSOCIATION OF TYPE AND NUMBER OF D’AMICO HIGH-RISK CRITERIA WITH RATES OF PATHOLOGICALLY NON ORGAN CONFINED PROSTATE CANCER
98. PD17-03 COMPARATIVE ANALYSES OF MICRO-ULTRASOUND VERSUS MRI-TARGETED BIOPSY FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER. PRELIMINARY RESULTS FROM THE PROSPECTIVE US-MIRROR TRIAL
99. MP15-19 CAN LOW RISK DISEASE OUTSIDE THE INDEX LESION BE LEFT UNTREATED IN MEN SUITABLE FOR FOCAL THERAPY? DEVELOPMENT OF NOVEL CRITERIA TO IDENTIFY POTENTIAL CANDIDATES FOR FOCAL THERAPY AMONG PATIENTS WITH INTERMEDIATE RISK PROSTATE CANCER AND POSITIVE MULTI-PARAMETRIC MRI
100. MP15-20 SURVIVAL AFTER RADICAL PROSTATECTOMY VS. RADIATION THERAPY IN DUCTAL CARCINOMA OF THE PROSTATE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.